Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer
January 25 2021 - 4:05PM
via NewMediaWire -- Timber Pharmaceuticals, Inc.
("Timber" or the “Company”) (NYSE American: TMBR), a
biopharmaceutical company focused on the development and
commercialization of treatments for rare and orphan dermatologic
diseases, today announced the appointment of Alan Mendelsohn, M.D.,
as Chief Medical Officer. Dr. Mendelsohn assumes the roles and
responsibilities of Amir Tavakkol, Ph.D., who will be stepping down
as the Company’s Chief Scientific Officer.
“We are pleased to welcome Dr. Mendelsohn to our
management team. Dr. Mendelsohn recently supported the approval and
launch of a new treatment for moderate to severe plaque psoriasis
and has a deep understanding of clinical development and medical
commercialization in dermatology,” said John Koconis, Chief
Executive Officer of Timber. “We also thank Dr. Tavakkol for his
support in establishing a strong scientific platform for us to
build on as we advance into clinical stage research.”
Dr. Mendelsohn is a board-certified pediatric
cardiologist with more than 20 years of experience in clinical
development and medical affairs. Prior to joining Timber, he served
as Associate Vice president of Dermatology Medical Affairs for Sun
Pharmaceuticals Industries. Previously Dr. Mendelsohn led the U.S.
rheumatology medical affairs team for Pfizer as a Senior Director
and was Senior Director of Immunology Research and Development for
Janssenwhere he worked on both rheumatology and dermatology
indications. He has also served in various leadership roles at
Centocor, Inc., a Johnson & Johnson company. Dr. Mendelsohn
holds a medical degree from the State University of New York Health
Science Center at Brooklyn.
“This is an exciting time to join Timber as the
Company continues to enroll patients in important studies for
underserved dermatologic diseases including congenital ichthyosis
and facial angiofibromas in tuberous sclerosis complex,” said Dr.
Mendelsohn. “I hope to use my experience to help our Timber team
successfully navigate the clinical development process through
regulatory reviews and look forward to serving patients and
families living with these rare conditions. As a former practicing
pediatric cardiologist, I have and will continue to focus my
passion on developing treatments for the underserved.”
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of treatments for rare and orphan dermatologic
diseases. The Company's investigational therapies have proven
mechanisms-of-action backed by decades of clinical experience and
well-established CMC (chemistry, manufacturing and control) and
safety profiles. The Company is initially focused on developing
non-systemic treatments for rare dermatologic diseases including
congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous
sclerosis complex (TSC), and scleroderma. For more information,
visit www.timberpharma.com.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, intellectual property rights, possible or
assumed future results of operations, business strategies,
potential growth opportunities and other statements that are
predictive in nature. These forward-looking statements are based on
current expectations, estimates, forecasts and projections about
the industry and markets in which we operate and management's
current beliefs and assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's Form 10-Q filed on
August 18, 2020 and its other filings with the Securities and
Exchange Commission. Prospective investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this press release. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information,
contact:
Timber Pharmaceuticals, Inc. John
Koconis Chief Executive Officerjkoconis@timberpharma.com
Investor Relations:Stephanie PrincePCG
Advisory(646) 863-6341 sprince@pcgadvisory.com
Media Relations: Adam DaleyBerry &
Company Public Relations (212) 253-8881adaley@berrypr.com
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Apr 2023 to Apr 2024